Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5561282 | 0.91 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPTNPC1 | |
| SCHEMBL5561821 | 0.90 | MEN1 (0.45) | MEN1KMT2AALDH1A1MAPTCDK2 | |
| SCHEMBL5561965 | 0.88 | F2 (0.45) | MEN1KMT2AALDH1A1MAPTNPC1 | |
| SCHEMBL5561897 | 0.87 | MEN1 (0.47) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL5556105 | 0.87 | MC4R (0.40) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL5562108 | 0.84 | MEN1 (0.48) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL5556324 | 0.83 | MEN1 (0.46) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL5561309 | 0.81 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL5563041 | 0.79 | GAA (0.39) | MEN1KMT2AALDH1A1MAPTNPC1 | |
| SCHEMBL5563683 | 0.79 | PTGER3 (0.42) | MEN1KMT2AALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631296-B1 | 2,3,4,5-TETRAHYDROBENZO¬F|¬1,4|OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-7060698-B2 | Benzoxazepinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20040235819-A1 | 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. | HOFFMANN-LA ROCHE INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235819-A1 | 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. | BACE1, BACE2, PSEN1 | MEN1 4394/4885KMT2A 1779/4885ALDH1A1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.